Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      

This page is updated frequently with new Receptor-related patent applications.




Date/App# patent app List of recent Receptor-related patents
04/07/16
20160097773 
 Intercellular labeling of ligand-receptor interactions patent thumbnailIntercellular labeling of ligand-receptor interactions
An sortase-mediated intercellular labeling method allowing for tracking ligand-receptor interaction both in vitro and in vivo; and uses thereof for tracking molecule interactions both in vitro and in vivo, identifying modulators of ligand-receptor interaction, identifying potential binding partners of a protein of interest, identifying b cells expressing high affinity b cell receptors to antigens, and identifying the antigen to which a t cell of interest binds.. .
Whitehead Institute For Biomedical Research


04/07/16
20160096902 
 Chimeric antigen receptor-targeting monoclonal antibodies patent thumbnailChimeric antigen receptor-targeting monoclonal antibodies
Provided are monoclonal antibodies that detect cd 19 car-modified immune cells and car-modified immune cells irrespective of the tumor associated antigen they target. Methods of using these functional monoclonal antibodies include, but are not limited to, detection, quantification, activation, and selective propagation of car-modified immune cells..
Board Of Regents, The University Of Texas System


04/07/16
20160096895 
 Binding members-513 patent thumbnailBinding members-513
This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (il-1r1). For example, isolated binding members specific for il-1r1 which competes with il-1 and il-1ra for binding to il-1r1 and binds il-1r1 with a kd of 10 pm or less when measured by kinexa™.
Medimmune Limited


04/07/16
20160096894 
 Antibodies to insulin-like growth factor i receptor patent thumbnailAntibodies to insulin-like growth factor i receptor
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor i receptor (igf-ir), which is preferably human igf-ir. The invention also relates to human anti-igf-ir antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins.
Amgen Fremont Inc.


04/07/16
20160096892 
 Treatment of cancer using a cd33 chimeric antigen receptor patent thumbnailTreatment of cancer using a cd33 chimeric antigen receptor
The invention provides compositions and methods for treating diseases associated with expression of cd33. The invention also relates to chimeric antigen receptor (car) specific to cd33, vectors encoding the same, and recombinant t cells comprising the cd33 car.
Novartis Ag


04/07/16
20160096888 
 Folate receptor 1 antibodies and immunoconjugates and uses thereof patent thumbnailFolate receptor 1 antibodies and immunoconjugates and uses thereof
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided..
Immunogen, Inc.


04/07/16
20160096887 
 Folate receptor 1 antibodies and immunoconjugates and uses thereof patent thumbnailFolate receptor 1 antibodies and immunoconjugates and uses thereof
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided..
Immunogen, Inc.


04/07/16
20160096876 
 Compositions and methods of treating disease with fgfr fusion proteins patent thumbnailCompositions and methods of treating disease with fgfr fusion proteins
The invention provides fgfr fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The fgfr fusion molecules can be made in cho cells and may comprise deletion mutations in the extracellular domains of the fgfrs which improve their stability.
Five Prime Therapeutics, Inc.


04/07/16
20160096875 
 Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells patent thumbnailCodon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
The present invention further provides expression vectors, and il-15 and il-15 receptor alpha combinations (nucleic acid and protein) that increase il-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of il-15 after dna, rna or protein administration in a subject (e.g.

04/07/16
20160096874 
 Mrg receptor modulators patent thumbnailMrg receptor modulators
The present invention is in the field of molecular biology, more particularly, the present invention relates to drug screening, assay development and identification and use of modulators for g-protein coupled receptor/ligand pair mrgx2/cxcl14 within drug discovery.. .
Bayer Pharma Aktiengesellschaft


04/07/16
20160096851 

Modulators of 5-ht receptors and methods of use thereof


Wherein r1, r2, r3, r4, r5, a, y1, y2, and y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, processes for making such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds..

04/07/16
20160096833 

Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mglur5


Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Vanderbilt University


04/07/16
20160096828 

Indole-1-carboxamides as kinase inhibitors


Or a pharmaceutically acceptable salt thereof, wherein r1, r2, r3, r4, r5, r6, r7, and x are as defined herein. The compounds of formula i are useful as receptor tyrosine kinase (rtk) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases..

04/07/16
20160096823 

Aminopyridyloxypyrazole compounds


The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (tgfβr1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.. .
Eli Lilly And Company


04/07/16
20160096811 

Benzoisothiazole compounds and use in preparation of antipsychotic drugs


Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine d3 receptor, 5-ht1a receptor and 5-ht2a receptor, but also can observably improve the symptoms of schizophrenia relevant to apomorphine model and mk-801 model mice, with oral absorption being good, safety being high and side-effect being less, and having developmental value as new anti-neurotic disease drugs.
Shanaghai Institute Of Pharmaceutical Industry


04/07/16
20160096803 

Crystal of pyrrole derivative and producing the same


The present invention provides a production intermediate of an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, a method for producing the same, and a crystal thereof. A method for producing an atropisomer of a pyrrole derivative including a step of resolving a compound represented by the following general formula (i) [wherein r1 represents a methyl group or a trifluoromethyl group, r2 represents a hydrogen atom or a c1-c3 alkoxy group, and n represents an integer selected from 1 to 3] into its atropisomers, characterized by using an optically active amine having a cinchonine skeletal formula, and a crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxamide..
Daiichi Sankyo Company, Limited


04/07/16
20160096316 

Methods of making articles using structured tapes


Methods of making articles using structured tapes are disclosed. The structured tapes may include a structured template layer having a structured surface and an opposed second surface and an uncured backfill layer, the uncured backfill layer has a lower refractive index than the structured template layer, and the uncured backfill layer has a structured surface conforming to the structured surface of the structured template layer and an opposed second surface.
3m Innovative Properties Company


04/07/16
20160095921 

Combinations and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of c-c chemokine receptor 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies


Provided herein are compositions, methods and kits for treating inflammatory bowel disease (ibd) such as crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with ibd a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (ccr9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab.
Chemocentryx, Inc.


04/07/16
20160095895 

Highly concentrated formulations of soluble fc receptors


The present invention relates to novel formulations of soluble fc receptors and especially to formulations containing high concentrations of soluble fcγriib receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved..
Suppremol Gmbh


04/07/16
20160095854 

Arylpiperazine opioid receptor antagonists


Where r, y3, r1, r2, r3, r4 and r5 are as defined herein.. .

04/07/16
20160095849 

Crystalline form of a quinolinone-carboxamide compound


The invention provides a crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1s,3r,5r)-8-[(r)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with 5-ht4 receptor activity, and processes useful for preparing such crystalline salt forms..
Theravance Biopharma R&d Ip, Llc


04/07/16
20160095842 

Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer


A pharmaceutical combination comprising an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound of formula (i) or a pharmaceutically acceptable salt thereof and a fibroblast growth factor receptor (fgfr) kinase inhibitor, particularly for simultaneous, separate or sequential use for the treatment of a cancer; use of such pharmaceutical combination for the preparation of a medicament for the treatment of a cancer; use of such pharmaceutical combination for the treatment a cancer; a method for treating a cancer comprising administering to a subject having said cancer a jointly therapeutically effective amount of such combination; and related pharmaceutical compositions or kits thereof.. .

04/07/16
20160095840 

Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist


Combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.. .
Glaxo Group Limited


04/07/16
20160095823 

Methods of using propofol derivatives for analgesia


The present invention concerns compounds derived from the anaesthetic propofol that are useful as analgesics and methods of using the same. The compounds act as co-activators of strychnine-sensitive glycine receptors and may have greater activity at those glycine receptors than at gabaa..
Medizinische Hochschule Hannover


03/31/16
20160093273 

Dynamic vision sensor with shared pixels and time division multiplexing for higher spatial resolution and better linear separable data


A dynamic vision sensor (dvs) where pixel pitch is reduced to increase spatial resolution. The dvs includes shared pixels that employ time division multiplexing (tdm) for higher spatial resolution and better linear separation of pixel data.
Samsung Electronics Co., Ltd.


03/31/16
20160091806 

Electrophotographic photoreceptor and image forming apparatus


The invention provides an image forming apparatus and an electrophotographic photoreceptor, comprising: a conductive support; and at least a charge generation layer and a charge transport layer on the conductive support, wherein said charge generation layer contains a hydroxygallium phthalocyanine synthesized using a halogen solvent, said charge transport layer contains a polyester resin having a specific structural unit, and said charge transport layer is formed using a non-halogen solvent.. .
Mitsubishi Chemical Corporation


03/31/16
20160091805 

Fluorinated structured organic film photoreceptor layers


A method of forming an overcoat layer. The method comprises providing a substrate having an imaging structure formed thereon, the imaging structure comprising (i) a charge transport layer and a charge generating layer, or (ii) an imaging layer comprising both charge generating material and charge transport material.
Xerox Corporation


03/31/16
20160091804 

Image forming method, image forming apparatus, and process cartridge


Wherein, when a content of the fatty acid metal salt particles with respect to the entire weight of the toner is set as rmf, an average abrasion rate of the electrophotographic photoreceptor is set as wh, a maximum abrasion rate of the electrophotographic photoreceptor is set as whmax, and a minimum abrasion rate of the electrophotographic photoreceptor is set as whmin, and an average abrasion rate of the electrophotographic photoreceptor is set as wl, a maximum abrasion rate of the electrophotographic photoreceptor is set as wlmax, and a minimum abrasion rate of the electrophotographic photoreceptor is set as wlmin.. .

03/31/16
20160091501 

Method for diagnosing and treating crohn's disease


The present invention relates to an in vitro method for diagnosing crohn's disease or for determining predisposition in a person to develop crohn's disease, by detecting an overexpression of the cd66c receptor in subjects suffering from said disease or at risk of developing the disease. The invention also relates to preventive or curative treatment for crohn's disease..
Lesaffre Et Compagnie


03/31/16
20160091488 

Cells as a model to identify potential taste modulators


Co-expression of t1r2 and t1r3 results in a taste receptor that responds to sweet taste stimuli, including naturally occurring and artificial sweeteners. Cells such as u2-os, which express a functional sweet receptor, can be used in cell-based assays to detect cellular responses to tastants..
Pepsico, Inc.


03/31/16
20160090968 

A lightning protection system for a wind turbine blade


A wind turbine blade is described having a lightning protection system, wherein the lightning protection system is arranged to protect conductive elements or modules used in or on the blade. In one aspect, the lightning protection system comprises a conductive band to be arranged around the circumference of the blade at the location of an internal conductive module, to prevent a lightning strike from penetrating the blade and potentially damaging the internal module.
Lm Wp Patent Holding A/s


03/31/16
20160090633 

Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor


Disclosed herein are methods of identifying a cancer patient that will be responsive to treatment with a fibroblast growth factor receptor (fgfr) inhibitor and methods of treating cancer patients. The methods involve evaluating a biological sample from the patient for the presence of one or more fgfr mutants from a fgfr mutant gene panel.
Janssen Pharmaceutica Nv


03/31/16
20160090628 

Detection of mineralocorticoid receptor activation and personalized antihypertensive therapy based thereon


Provided herein are compositions and methods for the assessment of mineralocorticoid receptor activation or repression, and methods of customizing antihypertensive therapies based thereon. In particular, assays are provided for the detection of targets of mineralocorticoid receptor activation..
The Regents Of University Of Michigan


03/31/16
20160090402 

Peptide domain required for interaction between the envelope of a virus pertaining to the herv-w interference group and an hasct receptor


A peptide domain necessary for an interaction between an envelope of a virus belonging to an herv-w interference group and an hasct receptor comprises (i) an n-terminus motif having an amino acid sequence selected from the group consisting of: seq id no. 1 to seq id no.
Biomerieux


03/31/16
20160090394 

Mobilizing cells expressing a type 4 cxc chemokine receptor with 4-amino pyrimidine compounds


The method can be used to treat cancer and myocardial infarction.. .

03/31/16
20160090378 

Estrogen receptor modulators and uses thereof


Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors..
Genentech, Inc.


03/31/16
20160090377 

Azetidine estrogen receptor modulators and uses thereof


Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors..
Genentech, Inc.


03/31/16
20160090374 

Bicyclic derivative containing pyrimidine ring, and preparation method therefor


The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-ht4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (gerd), constipation, irritable bowel syndrome (ibs), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like..
Yuhan Corporation


03/31/16
20160090372 

Compounds as tyrosine kinase modulators


The present invention is directed to novel compounds of formula i. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors..
Allergan, Inc.


03/31/16
20160089435 

Pan-her antibody composition


The present invention is directed to improved therapeutics against receptors within the egfr/erbb/her family that more broadly interfere with multiple members of the her family (pan-her inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy.
Symphogen A/s


03/31/16
20160089434 

Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor


A novel combination comprising the mek inhibitor n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and/or a b-raf inhibitor, particularly n-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and an anti-pd-l1 antibody; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of mek and/or b-raf and/or neutralizing or inhibiting the interaction between pd-l1 and its receptor, e.g. Pd-1, is beneficial, eg.
Novartis Ag


03/31/16
20160089385 

Vitamin d receptor agonists to treat diseases involving cxcl12 activity


Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon-like peptide (glp) agonists (such as glp-1 agonists, for example byetta®), by administration of a vitamin d receptor agonist (such as vitamin d, vitamin d analogs, vitamin d precursors, and vitamin d receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes..
Salk Institute For Biological Studies


03/31/16
20160089379 

Treatment of neurological and other disorders


Methods and implants for treating neurological, muscular and other cells having an electrical potential, with an infusion of antagonists or inverse agonists (such as flumazenil for the benzodiazepine receptor, or naltrexone for the opiate receptor or other antagonist for other receptor) at rates that are so low that only a small percentage of receptors have the antagonist effect at any one time.. .
Palmaya Pty Ltd


03/31/16
20160089378 

Treatment of osteoarthritis pain


This invention discloses a method of treatment of osteoarthritis pain by administration of a histamine h3 receptor antagonist, described herein, a salt thereof, or a composition comprising such compound or salt.. .
Abbvie Inc.


03/31/16
20160089364 

Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception


The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2h-indazole as novel ep2 receptor antagonists in combination with cox inhibitors.
Bayer Pharma Aktiengesellschaft


03/31/16
20160089354 

Substituted phenyl aziridine precursor analogs for inhibiting androgen-independent cancer cell growth


Disclosed are methods and pharmaceutical compositions for modulating one or more steroidal receptor activities. The methods typically utilize and the pharmaceutical compositions typically include one or more substituted phenyl aziridine precursors, their respective aziridines, analogs thereof, derivatives thereof, or pharmaceutically acceptable salts thereof such as cpda.
Northwestern University


03/31/16
20160089352 

Cell membrane transport promoter for selective 5-ht1a serotonin receptors


A cellular membrane trafficking promoter for a 5-ht1a serotonin receptor containing 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid as an active ingredient, and the like.. .

03/31/16
20160089349 

Cb2 receptor ligands for the treatment of psychiatric disorders


The present invention provides cannabinoid type 2 (cb2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-o-methylhonokiol for treating attention deficit hyperactivity disorder (adhd) and tourette's syndrome..
Ariel - University Research And Development Company, Ltd.


03/31/16
20160089348 

Use of an s1p receptor agonist


The present invention relates to new uses of s1p receptor modulator or agonist such as fingolimod, for reducing or delaying the progression of cerebral atrophy.. .

03/31/16
20160089346 

Method of treatment for body contouring


Provided herein are methods involving body contouring applications including treatments to reduce subcutaneous fat. The methods include the determination of patient suitability for body contouring treatment by evaluating one or more patient assessments.
Neothetics, Inc.


03/31/16
20160089313 

Method for searching for malodor control agent, malodor control agent, and malodor control method


Provided are a method for searching for a malodor inhibitor by using the response of an olfactory receptor as an indicator; a method for inhibiting malodor based on the antagonism of olfactory receptors; and a malodor inhibitor. Disclosed are a method for searching for a malodor inhibitor, the method including: adding a test substance and a malodor-causing substance to any one olfactory receptor selected from the group consisting of or51e1, or2w1, or10a6, or51i2, and or51l1, measuring the response of the olfactory receptor to the malodor-causing substance, identifying the test substance that suppresses the response of the olfactory receptor on the basis of the measured response, and selecting the identified test substance as a malodor inhibitor; an antagonist to any one olfactory receptor selected from the group consisting of or51e1, or2w1, or10a6, or51i2, and or51l1; a method for inhibiting malodor using the antagonist..
Kao Corporation


03/24/16
20160085164 

Electron transport material, electrophotographic photoreceptor, process cartridge, and image forming apparatus


Wherein x represents an oxygen atom or ═c(cn)2; r1, r2, r3, r4, r5, r6, and r7 each independently represent a hydrogen atom, a halogen atom, a linear or branched alkyl group, an alkoxy group, an aryl group, or an aralkyl group; r8, r9, and r10 each independently represent a hydrogen atom, a halogen atom, a linear or branched alkyl group, an aralkyl group, an aryl group, —r11—o—r12, or —r13—co—o—r14; r11 represents a linear or branched alkylene group; r12 represents a linear or branched alkyl group; r13 represents a single bond or a linear or branched alkylene group; and r14 represents a linear or branched alkyl group, an aryl group, or an aralkyl group, provided that at least two or more groups of r8, r9, and r10 represent a group other than a hydrogen atom.. .

03/24/16
20160085163 

Electrophotographic photoreceptor, process cartridge, and image forming apparatus


An electrophotographic photoreceptor includes a conductive substrate and a photosensitive layer provided on the conductive substrate, wherein an outermost surface layer of the electrophotographic photoreceptor is a cured film of a composition containing a reactive charge transporting material and silica particles having a hydrophobization-treated surface.. .
Fuji Xerox Co., Ltd.


03/24/16
20160084847 

Stabilized liquid formulations containing receptors


Methods and reagents are disclosed for preparing a liquid solution of a receptor. The methods comprise combining in a liquid medium the receptor, a chelating agent and a c2-c6 polyol.
Siemens Healthcare Diagnostics Inc.


03/24/16
20160084834 

Taste receptor internalization assay


This disclosure provides a taste receptor internalization assay useful for identifying taste modulators.. .
Pepsico, Inc.


03/24/16
20160083714 

Mutant cyaa polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell


The invention relates to mutant cyaa/e570q+k860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the cd11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host.
Institute Of Physiology Of The Ascr, V.v.i.


03/24/16
20160083480 

Bispecific her2 and her3 antigen binding constructs


Described herein are isolated bi-specific antigen binding constructs, e.g., antibodies. The bi-specific antigen binding constructs include two antigen binding polypeptide constructs, e.g., a fab and an scfv.
Zymeworks Inc.


03/24/16
20160083471 

Folate receptor 1 antibodies and immunoconjugates and uses thereof


Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided..
Immunogen, Inc.


03/24/16
20160083462 

Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same


The present invention relates to compositions and methods for creation of vector nucleic acid sequences (e.g., retroviral nucleic acid sequences) that comprise two or more exogenous nucleic acid sequences that encode highly homologous (e.g., identical) polypeptide sequences, yet wherein at least one of the exogenous nucleic acid sequences has been mutated using degenerate codons for purpose of reducing homology between the two or more exogenous nucleic acid sequences while maintaining the encoded polypeptide sequence. Preferred nucleic acid sequences include those encoding multi-chimeric immune receptor (cir) genes.
Roger Williams Hospital


03/24/16
20160083449 

T cell immunotherapy specific for wt-1


The present disclosure provides high affinity and enhanced affinity t cell receptors specific for human wilms tumor protein 1 (wt-1) epitopes for use in treating diseases or disorders, such as cancer cells that overexpress wt-1.. .
Fred Hutchinson Cancer Research Center


03/24/16
20160083444 

Novel feline erythropoietin receptor agonists


The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.. .
Askgene Pharma, Inc.


03/24/16
20160083442 

Inhibitors of the t cell-specific alternative p38 activation pathway and methods of use


In t lymphocytes, p38 mitogen activated protein kinase (mapk) can be activated through an alternative pathway that involves phosphorylation at tyrosine 323. Disclosed herein is the identification of a minimal region of the growth arrest and dna damage-inducible alpha (gadd45α) protein that is required for binding to and inhibition of tyrosine 323-phosphorylated p38 in t cells.
The U.s.a, As Represented By The Secretary Department Of Health And Human Services


03/24/16
20160083428 

Inhibitors of the eph-a receptor and uses thereof


Eph a receptor inhibitor peptides, and particularly eph a4 receptor inhibitor peptides, are provided. The peptides comprise a sequence derived from the g-h loop of ephrin a4.
University Of Haifa


03/24/16
20160083425 

Proprotein convertase subtilisin kexin type 9 (pcsk9) allosteric binding ligands to modulate serum low density lipoprotein (ldl) levels


This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein pcsk9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 da.
Srx Cardio, Llc


03/24/16
20160083403 

Boron-containing diacylhydrazine compounds


And the pharmaceutically acceptable salts and solvates thereof, wherein a, r4, and r5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems.

03/24/16
20160083370 

Substituted heteroaryl compounds and methods of use thereof


Provided herein are novel heteroaryl compounds, pharmaceutically acceptable salts and pharmaceutical formulations thereof for selectively inhibiting serotonin reuptake and/or acting as 5-ht1a receptor agonists. Also provided herein are pharmaceutical compositions comprising the heteroaryl compounds and methods of using the pharmaceutical compositions in treating central nervous system (cns) dysfunction in a mammal, especially a human being..
Sunshine Lake Pharma Co., Ltd.


03/24/16
20160083363 

Substituted indoles as selective protease activated receptor 4 (par-4) antagonists


Embodiments of the invention include substituted indole compounds and compositions thereof to inhibit protease activated receptor-4. Also described are methods of preparation of compositions and methods for treating diseases related to thrombotic disorders by administration of the composition..
Vanderbilt University


03/24/16
20160083350 

A nk3 receptor antagonist compound (nk3ra) for use in a the treatment of polycystic ovary syndrome (pcos)


A method for treating polycystic ovarian syndrome and related conditions with a compound (i): or a pharmaceutically acceptable salt thereof.. .
Astrazeneca Uk Limited


03/24/16
20160083342 

Sulfur derivatives as chemokine receptor modulators


The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.. .
Allergan, Inc.


03/24/16
20160082761 

Image transfer material and polymer composition


Provided is an image transfer material, comprising a support, optionally at least one barrier layer, a melt transfer layer, and an image receiving layer. Also provided is a process for preparing the image transfer material.
Mj Solutions Gmbh


03/24/16
20160082130 

Dosage forms and methods for diagnosing sympathetic nervous system dysfunction


Described are methods for detecting and/or diagnosing systemic sympathetic nervous system dysfunction or disease in a subject. One embodiment comprises using a topical apraclonidine eye drop to detect an ocular condition indicative of sympathetic dysfunction or disease in a subject with guillain-barré syndrome (gbs).

03/24/16
20160082122 

Non-immunogenic and nuclease resistant nucleic acid origami devices and compositions thereof


Nucleic acid origami devices are provided that are non-immunogenic and/or resistant to nucleases, which may be activated by one or more external cues, such as ligands, glucose concentration or electromagnetic fields; or used for attenuation or prevention of internalization of cell-surface receptors or prolongation of shelf-life of active agents. Further provided are methods for treating diabetes and methods for preparing the devices..
Bar-ilan University


03/24/16
20160082118 

Glp-1 receptor agonist peptide gastrin conjugates


The present invention relates, inter alia, to certain peptide conjugates, and to the use of the conjugates in the treatment of a variety of diseases or disorders, including diabetes (type 1 and/or type 2) and diabetes-related diseases or disorders.. .
Zealand Pharma A/s


03/24/16
20160082117 

Low molecular weight polyethylene glycol drug conjugates having improved drug biological activity


Provided are polyethylene glycol drug conjugates of general formula (i), (ii) or (iii) and pharmaceutical compositions and a use thereof. The conjugates are formed by combining low molecular weight polyethylene glycol with 2-4 drug molecules.
Jenkem Technology Co.,ltd.(tianjin)


03/24/16
20160082112 

Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer


The present invention relates to compounds which function as antibody mimetic compounds. These compounds are bifunctional/multifunctional compounds which contain at least one cancer cell binding moiety which selectively binds to prostate specific membrane antigen (psma) and a fc receptor binding moiety which modulates an fc immune receptor, preferably a fcγri receptor.
Yale University


03/24/16
20160082105 

Antibody buffering of a ligand in vivo


Compositions and methods are provided in embodiments directed to maintaining a desired concentration range of one or more drugs in a subject, and in particular embodiments to maintaining a desired drug concentration in a body compartment in a subject, based on the surprising discovery that antibodies persist in solution in body compartments such that antibody-antigen equilibrium principles can counteract drug clearance mechanisms. One or more antibodies are selected that have a dissociation constant kd that is similar to the desired drug concentration, wherein kd is independent of the affinity of the drug for a specific drug target (receptor) in the subject..
Arrowsmith Technologies Corporation


03/24/16
20160082104 

Methods and compositions for the treatment of proliferative and pathogenic diseases


The invention features peptide fragments containing domain 4 of the streptococcus intermedius intermedilysin (ily) protein and the use of these fragments to sensitize cancer cells to antibody-based anticancer treatments. The invention also features use of these fragments to treat patients infected with microbial pathogens expressing cd59 or cd59-like molecules.
President And Fellows Of Harvard College


03/24/16
20160082079 

Wnt antagonist and methods of treatment and screening


The present invention relates to compositions comprising wnt antagonists and methods of treating wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such wnt antagonists. In particular, the invention discloses soluble fzd, sfrp and ror receptors and their use..
Oncomed Pharmaceuticals, Inc.


03/24/16
20160082045 

Engineering and delivery of therapeutic compositions of freshly isolated cells


The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as pbmc, pbl, t (cd3+ and/or cd8+) and natural killer (nk) cells.
Maxcyte, Inc.


03/24/16
20160082020 

Methods and compositions for stimulating reepithelialisation during wound healing


The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mineralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing..
Universite Paris Descartes


03/24/16
20160082007 

Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists


The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity.
Allergan, Inc.


03/24/16
20160082004 

Selective opioid compounds


Which relates to morphinan compounds useful as μ, δ and/or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.. .

03/24/16
20160081995 

Selective nr2b antagonists


The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the nr2b receptor and may be useful for the treatment of various disorders of the central nervous system..
Bristol-myers Squibb Company


03/24/16
20160081956 

Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes


In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a gaba receptor agonist, in an amount sufficient to ameliorate said one or more symptoms.
The Regents Of The University Of California


03/24/16
20160081949 

Dosage regimen for a s1p receptor agonist


S1p receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.. .

03/24/16
20160081901 

Compositions and methods for hair growth


The present invention provides compositions comprising a bradykinin receptor b2 agonist or an angiotensin ii receptor (atir) antagonist, and methods using such compositions to increase/promote hair growth or reduce/delay hair loss.. .
Wuhan Optics Valley Bridgebiomed International Corporation


03/24/16
20160081550 

Nth leadless electrode telemetry device, system and use


A disclosed telemetry system comprises an nth number of telemetry devices and an equal number of standard disposable circular electrode patches. A body of each telemetry device in the system includes a female snap receptor configured to attach to a single male snap post of an electrode patch.

03/24/16
20160081314 

Chimeric antigen receptors


Provided herein are methods and compositions related to chimeric antigen receptors (cars) having antigen binding domains derived from an immunoglobulin (ig) and constant domains derived from a t cell receptor (tcr).. .
Regeneron Pharmaceuticals, Inc.


03/24/16
20160081313 

Materials and methods for producing animals with short hair


The subject invention provides materials and methods for producing animals with short hair length. In a preferred embodiment, this is accomplished by altering in the animal the nucleotide sequence that encodes the prolactin receptor (prlr) protein such that a truncated version of the protein is produced.
Aggenetics, Inc.






Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.9108

4646

2 - 1 - 102